When can investors expect sales?
Becoz it's no good if the kits can't sell |
This dog share couldn't break 2.3p with massive placing looming |
A school kid would have made some instant profit selling lemonade. GDR asva company hasn't made a penny |
How much money is GDR making?
£0? Nevermind |
So the Middle East is rather relevant I think, as cited in post 937. |
Through detailed examination of previous NICE reports, I did indeed find reference to ethnic breakdown relevance.
One of several points by Nicky J. WeltonOrcid, University of Bristol, Bristol, UK
Joe Carroll, University of Bristol, Bristol, UK in a peer review.
' It would be better for the authors to look at the LOF rates in the UK population that uses the NHS based on its current ethnic breakdown rather than to focus on those of European ancestry alone. More so considering the LOF rates are higher in non-European populations.
Part of the issue with dipryridamole as an alternative is that it is poorly tolerated compared to aspirin and clopidogrel. Is there data available about the rates of discontinuation of dipyridamole within stroke patients? Could that information be incorporated into your models?' |
Hey!
The Middle East!
'In just 1 WEEK, Genedrive are exhibiting at MedlabMiddle East!
Visit stand Z2.K11 to discover our innovative pharmacogenetic testing products.
Contact enquiries@genedrive.com to book a meeting.' |
'In just 1 WEEK, Genedrive are exhibiting at MedlabMiddle East!
That translates to no sales, so they go there in hope someone will buy their goods |
'Background: People who have experienced a stroke are at high risk of recurrent strokes. Clopidogrel is prescribed to people who have had a non-cardioembolic stroke. There is evidence that clopidogrel is not effective for patients with CYP2C19 loss-of-function alleles. Pharmacogenetic testing is a potential strategy to identify such patients and guide prescription of appropriate antiplatelet treatment. This study aimed to provide an early estimate of the cost-effectiveness of using a point-of-care pharmacogenetic CYP2C19 test in the UK National Health System.' |
From NICE above.
'Populations
People who have had non-cardioembolic ischaemic stroke or transient
ischaemic attack for whom clopidogrel treatment is being considered.
Where data permits, the following subgroups may be considered:
• People of different ethnicities
• People with different severity of stroke (TIA, moderate or severe ischaemic
stroke)
• People who would receive clopidogrel earlier than 2 weeks after onset of
symptoms
• Children and young people.'
H |
From memory the stroke test is beneficial to people of a certain background, in that our DNA has a family reference, and a higher incidence in this particular case of needing a different medication to benefit.
Now where did I read that?
IMO |
Hey!
The Middle East!
'In just 1 WEEK, Genedrive are exhibiting at MedlabMiddle East!
Visit stand Z2.K11 to discover our innovative pharmacogenetic testing products.
Contact enquiries@genedrive.com to book a meeting.' |
Thank goodness for some good research and sensible posting. |
False rise for the purpose of a placing |
Further news this time will skyrocket these shares way past 5p |
I see the pathetic troll jailbird is posting his garbage on the other thread
The idiot was probably waiting to buy , but the price took off yesterday so hence his deramps hahaha
Hey troll short term target is 4p to 5p.
Hope that helps you |
PBJust be wary of cash call now.See what the strike price will be |
Ah ok thats an interesting one Interests me as my dad had a TIA and is on clopidogrelMarket there for this one |
Gone NT to buy even 25,000 @ 2.35p |
I'm holding to hit that top of the bowl at 10p. |
The price has fallen from 5p after CYP2C19 was approved in July 2024.
Share price will rerate abck that level over the coming days/weeks.
The valuation is just far too LOW. |
Meanwhile it's begging to break out of this range. Won't be long now. |
It's not about the deafness product, it's all about the stroke one, that's where the money is. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
